OncoMatch/Clinical Trials/NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Is NCT06542250 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AZD5492 for b-cell malignancies.
Treatment: AZD5492 — This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CD20 overexpression (CD20+)
Histologically documented CD20+ mature B-cell neoplasm
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Exception: within 180 days
Prior allogeneic HSCT within 180 days
Cannot have received: autologous stem cell transplant
Exception: within 90 days
prior autologous HSCT within 90 days
Cannot have received: cell therapy
Exception: within 90 days
cell therapy within 90 days of start of therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · La Jolla, California
- Research Site · Boston, Massachusetts
- Research Site · Hackensack, New Jersey
- Research Site · New York, New York
- Research Site · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify